Advanced Search

per page
  Report Title Date Provider Type Pgs Price

Aldeyra Therapeutics Inc: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.

This report is essential reading for any serious investor, providing comprehensive financial information on a company's perfo...

23 Jul 2016 Reuters Investment Profile 12 $20.00

Thomson Reuters Stock Report - Aldeyra Therapeutics Inc (ALDX-O)

StockReports+ gathers Thomson Reuters independent research, ratings and market data into a single report that optimizes the i...

26 Jul 2016 Thomson Reuters Stock Report 12 $25.00

ValuEngine Rating and Forecast Report for ALDX

Advanced academic research that brings you superior investment strategies in an actionable format. The most comprehensive and...

24 Jul 2016 ValuEngine, Inc. 11 $25.00


", the world's largest market forecasting firm with subscribers in 83 different countries provide forecasts of...

23 Jul 2016 Pechala's Reports 2 $25.00

Laidlaw: ALDX: 1Q16: Positive POC top-line results of NS2 in noninfectious anterior uveitis Phase II trial

This morning, ALDX reported 1Q16 financial results with a net loss of ($5.0MM) and net loss per share of ($0.51). ALDX ended ...

09 May 2016 Laidlaw & Company 8 $25.00

ALDX: 4Q15: Top-line results of NS2 in two Phase II trials expected in 2Q/3Q16 are near-term catalysts

This morning, ALDX reported 4Q15 financial results with a net loss of ($4.3MM), net loss per share of ($0.44) and cash of $27...

30 Mar 2016 Laidlaw & Company 7 $25.00

ALDX.OQ - Event Transcript of Aldeyra Therapeutics Inc conference call, Mar. 30, 2016 / 8:30AM ET

Edited Event Transcript of ALDX.OQ conference call, Mar. 30, 2016 / 8:30AM ET Boston, Mar 31, 2016 (Thomson StreetEvent...

30 Mar 2016 Thomson Reuters StreetEvents 9 $75.00

ALDX: Positive NS2 in allergic conjunctivitis Phase IIa trial results would be a major clinical validation for aldehyde trapping

This morning, ALDX reported positive NS2 in allergic conjunctivitis (AC) Phase IIa trial results. The drug achieved statist...

29 Feb 2016 Laidlaw & Company 8 $25.00

Interview with the CEO, President and Director: Aldeyra Therapeutics Inc. (NASDAQ:ALDX)

12 Feb 2016 Wall Street Transcript ,The 3 $50.00

ALDX – Last patient for the NS2 in allergic conjunctivitis in Phase II trial completed dosing—ahead of our projection

This morning, ALDX reported that the NS2 in allergic conjunctivitis Phase II trial has completed dosing the last patient, and...

16 Dec 2015 Laidlaw & Company 7 $25.00